提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://jamanetwork.com/journals/jamaoncology
3、投稿网址：https://manuscripts.jamaonc.com/
4、官网邮箱：jamaonc@jamanetwork.org
5、期刊刊期：月刊，一年出版12期。
2021年8月2日星期一
投稿须知【官网信息】
For Authors
About JAMA Oncology
JAMA Oncology is an international peer-reviewed journal and the definitive journal for scientists, clinicians, and trainees in the field of oncology. JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
Journal Frequency and Access. JAMA Oncology is published online weekly, every Thursday, and in 12 print/online issues a year. The journal receives over 2.1 million online visits annually and more than 2.9 million article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program.
Editorial Information. The journal’s acceptance rate is 12%. The median time to first decision is 2 days, and 39 days with review. The journal's Impact Factor is 31.8, one of the highest ranking among oncology journals. All articles are published online first. Additional information on the types of articles published and editorial policies is available in the journal's Instructions for Authors.
Editorial Team. The founding Editor in Chief of JAMA Oncology is Mary L. (Nora) Disis, MD. Dr Disis is director of the UW Institute of Translational Health Science and the Center for Translational Medicine in Women's Health. She is also associate dean of the UW School of Medicine, dean of Research and Graduate Education, associate dean of Translational Science, Helen B. Slonaker Endowed Professor for Cancer Research, professor of Medicine and Oncology, and adjunct professor of Obstetrics & Gynecology and Pathology. For a complete listing of the journal's Editors and Editorial Board, see Editors and Publishers.
Mission Statement. JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
JAMA Oncology
ISSN 2374-2437 (Print)
ISSN 2374-2445 (Online)
Why Publish in JAMA Oncology?
JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.
Impact and Reach
Impact Factor of 31.8, one of the highest ranking among oncology journals
Over 2.1 million annual visits to the JAMA Oncology website; more than 2.9 million article views and downloads
International authors: 51% of submissions come from outside the United States
Extensive press coverage, with over 10,000 media mentions in 2020 and 2021 in outlets such as The Wall Street Journal, CNN, Forbes, and Reuters
Top Altmetric scores—JAMA Oncology published 18 of the top 50 articles among oncology journals
Number of citations, Altmetric score, page views, and PDF downloads tracked for your published article
Broad reach through related commentary, author audio interviews, podcasts, email alerts, social media, multimedia, and more than 63,000 followers on Twitter and Facebook
Prompt Decisions and Rapid Publication Timelines
Highly selective peer review and editorial evaluation, with 12% acceptance rate for all submissions
Median time to first decision: 2 days without external peer review; 39 days with review
Online First publication of all major articles
Author Service
User-friendly manuscript submission system and process
Prompt, expert review and consideration from our experienced editors
Highest standards followed to improve your accepted manuscript’s accuracy, reliability, and readability
CME credit available for lead authors who publish in JAMA Oncology
Opportunity for your work to be augmented with expert illustration, interactive features, video, audio, and visual abstract
Free public access: All research articles are free 12 months after publication on the journal's website
Open access: Authors of research articles may elect to pay for immediate open access on the day of publication
Direct deposit to PubMed Central: All research articles deposited directly in PubMed Central (PMC) for authors
Online extras: Ability to post supplemental content online and download your article’s tables and figures as PowerPoint slides
The JAMA Network advantage: Authors of papers not accepted by JAMA Oncology may have the option to have their papers and reviewers' comments automatically referred to one of the JAMA Network specialty journals and/or JAMA Network Open
Dedicated media team to promote your article to the news media and on social media
JAMA Network journals welcome manuscript submissions on diversity, equity, and inclusion. For example, see the Health Disparities Topic Collection and the list of articles on race, racism, and racial/ethnic disparities/inequities published during the last 5 years here.
For more information, see JAMA Oncology Instructions for Authors. Submit your manuscript at https://manuscripts.jamaonc.com.
Updated July 2021
Contact Information
JAMA Oncology, Mary L. (Nora) Disis, MD, Editor, Cancer Vaccine Institute, University of Washington, 850 Republican St, Box 358050, Seattle, WA 98109-4714; email: jamaonc@jamanetwork.org. Manuscripts should be submitted online at http://manuscripts.jamaonc.com.
How Do I?
Determine My Article Type
Categories of Articles
……
更多详情：
https://jamanetwork.com/journals/jamaoncology/pages/for-authors
